A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants

Exclusion Criteria

• •1. History or presence of disorders capable of significantly altering the absorption, metabolism, or elimination of drugs.
• •2. Abnormal blood pressure.
• •3. Any malignancy within the past 5 years except certain localized malignancies, or breast cancer within the past 10 years.
• •4. Has exclusionary psychiatric, hepatic, cardiovascular, gastrointestinal, respiratory, endocrine, neurological, hematological, or renal condition.
• •5. Current or chronic history of liver disease or known hepatic or biliary abnormalities.
• •6. Participants with exclusionary electrocardiogram findings.
• •7. Past or intended use of exclusionary medications or vaccines.
• •8. Exposure \> 4 new investigational products within 12 months, previous participation in this study, or current enrolment or participation in another investigational study.
• •9. ALT \>1.5x upper limit of normal (ULN), total bilirubin \>1.5x ULN, and/or estimated serum creatinine clearance \<60 mL/min.
• •10. History of or current infection with hepatitis B or hepatitis C.
• •11. Positive SARS-CoV-2 test, having signs and symptoms suggestive of COVID-19, or contact with known COVID-19 positive person.
• •12. Positive HIV antibody test.
• •13. Participants with positive results for illicit drug use, regular use of drugs of abuse, tobacco or nicotine-containing product use, and/or excessive alcohol use.